Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Nathan (Falls Church, United States of America). RISE-IIP: Riociguat for the treatment of pulmonary hypertension associated with idiopathic interstitial pneumonia. 1985

Member's Comments

No comment yet.

Related content which might interest you: Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis Source: Eur Respir J 2012; 40: 93-100 Year: 2012 Prevalence and impact of WHO group 3 pulmonary hypertension in advanced idiopathic nonspecific interstitial pneumonia Source: Eur Respir J, 52 (1) 1800545; 10.1183/13993003.00545-2018 Year: 2018 Sildenafil for treatment of associated pulmonary hypertension in patients with severe COVID-19 pneumonia. Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 Cyclosporine A in the treatment of idiopathic pulmonary fibrosis/usual interstitial pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 62s Year: 2002 Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle Year: 2018 Treatment of severe pulmonary hypertension in patients with interstitial lung disease: Results in 72 patients from the “HYPID” prospective study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 The classification, natural history and radiological/histological appearance of idiopathic pulmonary fibrosis and the other idiopathic interstitial pneumonias Source: Eur Respir Rev 2008; 17: 108-115 Year: 2008 Pulmonary hypertension in idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Pulmonary hypertension in patients with idiopathic pulmonary fibrosis Source: Eur Respir Mon 2012; 57: 148-160 Year: 2012 Diagnosis of pulmonary arterial hypertension in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 335s Year: 2005 Idiopathic pulmonary haemosiderosis revisited Source: Eur Respir J 2004; 24: 162-169 Year: 2004 Pulmonary hypertension is common in end-stage sarcoidosis Source: Annual Congress 2005 - Progresses in granolomatous lung disease Year: 2005 Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome Source: Eur Respir J 2010; 35: 105-111 Year: 2010 Vulnerability of fatal infection under steroid treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2002; 20: Suppl. 38, 354s Year: 2002 Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF treatment II Year: 2016 Interstitial lung diseases in childhood Source: ISSN=1025-448x, ISBN=1-904097-22-7, page=213 Year: 2002 Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia Source: Eur Respir J 2005; 25: 528-533 Year: 2005 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Non-pulmonary comorbidities in idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction Source: Eur Respir J 2015; 46: 1370-1377 Year: 2015